On this page
The research desk’s view
The same menu lists MOTS-c within a provider-evaluated peptide service. Consultation $249, or $349 with blood work; a MOTS-c fill requires a separate quote.
The listing, in detail
- Published service
- Scarsdale clinic; telehealth is stated for NY, NJ, CT, FL and CA
- Product/menu scope
- The same menu lists MOTS-c within a provider-evaluated peptide service.
- Cost position
- Consultation $249, or $349 with blood work; a MOTS-c fill requires a separate quote
- Decision condition
- Confirm exact product, individual eligibility and complete quote before a payment commitment
What the listing establishes
- The same menu lists MOTS-c within a provider-evaluated peptide service.
- Consultation $249, or $349 with blood work; a MOTS-c fill requires a separate quote
What it leaves unanswered
- The two consultation prices identify a concrete first decision: whether the stated blood work is included. Ask which tests are appropriate, what repeats and how results are reviewed. A five-state telehealth claim is more specific than national language but still needs confirmation for the intended visit and pharmacy fill.
- A provider listing does not establish individual eligibility or a clinical benefit.
The offer in its own setting
Protocol Health enters this comparison through a specific public listing: the same menu lists MOTS-c within a provider-evaluated peptide service. The service describes scarsdale clinic; telehealth is stated for NY, NJ, CT, FL and CA. That gives a reader a real place to begin asking questions, while leaving the clinical decision individual. It does not independently verify the pharmacy, establish that the product is appropriate or promise access. The starting evidence guide is useful background because the body's own MOTS-c signal and an administered product answer different research questions.
What deserves a second look
The two consultation prices identify a concrete first decision: whether the stated blood work is included. Ask which tests are appropriate, what repeats and how results are reviewed. A five-state telehealth claim is more specific than national language but still needs confirmation for the intended visit and pharmacy fill.
What the number does and does not mean
The public cost position is: Consultation $249, or $349 with blood work; a MOTS-c fill requires a separate quote. The written-quote comparison separates a medication amount from the costs of the wider care relationship.
Keep the biology separate from the promise
The distinction becomes clearer in the linked research appraisal. Its setting was cardiopulmonary-bypass patients and separate experimental lung-injury systems, and the outcomes concerned circulating MOTS-c, pulmonary injury and glycolysis/ferroptosis measures. The clinical component did not establish efficacy of administering MOTS-c to surgical patients. That observation helps a reader ask a narrower question of Protocol Health: which human outcome evidence supports the exact proposal? A scientific reason for interest is not a forecast of a personal response, and a convenient care pathway does not turn the experimental system into a patient treatment trial.
A different way to arrange care
For another service model, read the next provider comparison, which concerns clinically supervised program page; location and individual access need confirmation. The point is to compare the care arrangement and remaining questions, not imply the same product or endorse a clinical outcome. A service with a clearer price can still have unresolved clinical suitability; a consultation with no product guarantee can still provide useful assessment. We have not measured patient experience, support speed or the quality of a supplied preparation at either service.
Read the source
Research findings and provider statements are different evidence.
- Protocol Health official product or clinical-service pageCompany website